

Are Preoperative Corticosteroid Injections Associated with Increased Risk of Deep Infection after Unicompartmental Knee Arthroplasty?

Johnathon R McCormick¹, Elyse Jordan Berlinberg², Victoria Oladipo, Enrico Forlenza, Brian Forsythe³, COL. (ret) Tad L Gerlinger

¹Rush University Medical Center, ²Midwest Orthopedics At Rush, ³Midwest Orthopaedics At Rush


INTRODUCTION: Unicompartmental knee osteoarthritis (OA) may cause significant pain and disability. Prior to surgical intervention, pain may be managed via conservative modalities, including anti-inflammatory medications, physical therapy, and corticosteroid injections (CSI). However, many of these patients with isolated medial or lateral tibiofemoral degeneration may ultimately elect to undergo a unicompartmental knee arthroplasty (UKA). At the time of this study, it is unclear whether CSI prior to UKA impacts the likelihood of developing a postoperative infection. We sought to define the association between pre-operative CSI and infection within the 6 months after UKA, and whether it exhibits a time- or dose-dependent relationship.

METHODS: An administrative claims database was queried for all patients who underwent ipsilateral knee CSI within 6 months prior to undergoing UKA. Patients were excluded if laterality was not specified or if they did not have at least 6 months of pre-enrollment and 6 months of post-operative follow-up. Patients with a preoperative CSI were matched by age, sex, and Charlson Comorbidity Index (CCI) in a 1:1 ratio with controls who did not receive an intra-articular CSI in the 6 months prior to surgery. Rates of infection in the first 6 months after UKA were reported between CSI patients and controls. Time-dependent and dose-dependent relationships were modeled using multivariable logistic regression. Significance was set at $P=0.05$, and our sample size provided more than 80% power to detect a two-fold difference in rates of postoperative infection.

RESULTS: A total of 30,762 patients underwent UKA within the time queried, of which 25,342 (82.4%) had sufficient pre-enrollment, follow-up, and met the remainder of exclusion criteria. 10,562 patients within the UKA cohort had a CSI in the 6 months prior to surgery: 10,552 were matched to controls (n=10,552) who did not receive an intra-articular CSI (**Figure 1**). Baseline demographics were similar between groups after matching (**Table 1**). A total of 314 patients had a surgical site infection (SSI) after surgery (1.5%), 144 in patients with CSI (1.4%) and 170 controls (1.6%, OR=0.84, 95% CI 0.68-1.06, P=0.16). There was no significant difference in infection risk by timing of injection before surgery (**Table 2**). Although limited by low sample size (n=7 total infections), having 3 or more CSI in the 6 months prior to UKA was significantly associated with postoperative infection risk compared to having a single injection (OR 13.28, 95% CI 1.53-1115.58, P=0.019, **Table 3**). In univariable analysis, significant predictors of infection after UKA included younger age, male sex, increasing CCI, chronic obstructive pulmonary disease, chronic kidney disease, diabetes, obesity, and rheumatoid arthritis (**Table 4**). Multivariate analysis revealed that increasing CCI and younger age were independently associated with infection (**Table 5**).

DISCUSSION AND CONCLUSION: Administering ≤ 2 preoperative corticosteroid injections within 6 months prior to surgery is not associated with an increased risk of infection after UKA, although 3 or more CSI in this period may preclude an elevated risk. Significant medical comorbidity and younger age are also predictive of postoperative infection.

Figure 1. STROBE Diagram of a Matched Cohort Study of Patients with UKA +/- Preoperative CSI



	OR	2.50%	87.50%	P-Value
0-1 Month (N=7,400, 1=106)	0.983	0.739	1.250	0.36
1-2 Month (N=2,200, 1=16)	0.886	0.596	1.317	0.55
3-4 Month (N=1235, 1=28)	1.414	0.929	2.154	0.30
5-6 Month (N=164, 1=41)	0.000	0.000	Inf	0.97
6-7 Month (N=48, 1=1)	1.259	0.371	9.262	0.82
8-9 Month (N=47, 1=6)	0.000	0.000	Inf	0.88

*Model did not converge for these variables because 0 infections occurred in patients receiving an injection during this timepoint.

	OR	2.50%	97.50%	P-value
1 injection (N=9,560, I = 128)	Ref	—	—	—
2 injections (N=686, I = 15)	1.676	0.975	2.881	0.06
3 or more injections (N=6, I = 1)	15.281	1.526	115.379	0.00

[illegible]

Table 4: Univariable Predictors of Infection			
	OR	95%CI	P

	0.975	0.756	1.248	0.975
Injection within 1 Month Before Surgery	0.975	0.756	1.248	0.975
Myeloid Cell Before Surgery	1.248	0.756	1.248	0.975
1-Year Shuntless in Age	0.975	1.017	1.042	0.975
Male Gender	1.284	1.011	1.687	0.975
1-Point Increase in CCI	1.108	1.023	1.148	0.975
Smoking	1.837	1.185	1.942	0.975
Asthma	1.332	0.984	1.861	0.975
COPD	1.241	1.054	1.741	0.975
CAD	1.676	1.236	2.236	0.975
CAD	1.371	0.823	2.536	0.975
CAD	1.458	1.312	1.892	0.975
Diabetes	1.374	1.072	1.708	0.975
Hypertension	1.378	0.997	1.965	0.975
Hypothyroidism	0.927	0.700	1.236	0.975
Ischemic Heart Disease	1.666	0.775	1.665	0.975
1-Year Shuntless in Age	1.217	0.973	1.466	0.975
Obesity	1.931	1.178	1.947	0.975
Rheumatoid Arthritis	2.480	1.595	3.878	0.975

Table 5: Multivariable Predictors of Infection			
	OR	95%CI	P-Value

CSI within 1 Month Before Surgery	0.900	0.703	2.178	0.06
Multiple CSI in the Year Before Surgery	1.643	0.990	2.859	0.05
Male Gender	1.324	1.034	1.607	0.02
1-Point Increase in CCI	1.223	2.005	5.384	<0.00
1-Year Decrease in Age	1.833	1.023	1.044	<0.00